Comparison · NCT00486863-sae
Praziquantel at 12-16 Weeks Gestation vs Placebo Control at 12-16 Weeks Gestation: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Praziquantel at 12-16 Weeks Gestation vs Placebo Control at 12-16 Weeks Gestation: serious adverse events. Trial comparisons, record NCT00486863-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00486863-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.242 | 0.186 | 0.308 | wilson | |
| Risk in group 2 | 0.185 | 0.135 | 0.247 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0572 | -0.0266 | 0.14 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.31 | 0.881 | 1.95 | log | |
| Odds ratio, group 1 over group 2 | 1.41 | 0.853 | 2.32 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Praziquantel at 12-16 Weeks Gestation than on Placebo Control at 12-16 Weeks Gestation | 17.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Praziquantel at 12-16 Weeks Gestation | Praziquantel was administered orally as 60 mg/kg given in a split dose (30/mg/kg each) separated by 3 hours. | 45 | 186 | EG001 |
| Group 2 | Placebo Control at 12-16 Weeks Gestation | Placebo was made with the same color-coded gelatin capsules with the inert compound dextrose. | 34 | 184 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Solicited systemic symptoms were observed in clinic 24 hours after treatment and recorded for 14 days post treatment. Unsolicited adverse events and SAEs were evaluated at clinic visits and passively reported through 28 days post delivery.
Source ClinicalTrials.gov
Trial
- Title
- S. Japonicum and Pregnancy Outcomes
- NCT number
- NCT00486863
- Phases
- PHASE2
- Conditions
- Schistosomiasis
- Interventions
- Praziquantel, Placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2014-02-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00486863?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00486863-sae